2026-06-14T03:51:06Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/117672025-06-17T09:13:01Zcom_20.500.12105_15322com_20.500.12105_2051com_20.500.12105_2052col_20.500.12105_16960col_20.500.12105_16981col_20.500.12105_16982col_20.500.12105_19616

00925njm 22002777a 4500 dc Vega-Garcia, Nerea author Benito, Rocío author Esperanza-Cebollada, Elena author Llop, Marta author Robledo, Cristina author Vicente-Garcés, Clara author Alonso, Javier author Barragan, Eva author Fernández, Guerau author Hernández-Sánchez, Jesús M author Martín-Izquierdo, Marta author Maynou, Joan author Minguela, Alfredo author Montaño, Adrián author Ortega, Margarita author Torrebadell, Montserrat author Cervera, José author Sánchez, Joaquín author Jiménez-Velasco, Antonio author Riesco, Susana author Hernández-Rivas, Jesús M author Lassaletta, Álvaro author Fernández, José María author Rives, Susana author Dapena, José Luis author Ramírez, Manuel author Camós, Mireia author Spanish Society of Pediatric Hematology and Oncology (SEHOP). Group of Leukemia author 2020-11-26 The development of Next-Generation Sequencing (NGS) has provided useful diagnostic, prognostic, and therapeutic strategies for individualized management of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients. Consequently, NGS is rapidly being established in clinical practice. However, the technology's complexity, bioinformatics analysis, and the different available options difficult a broad consensus between different laboratories in its daily routine introduction. This collaborative study among Spanish centers was aimed to assess the feasibility, pros, and cons of our customized panel and other commercial alternatives of NGS-targeted approaches. The custom panel was tested in three different sequencing centers. We used the same samples to assess other commercial panels (OncomineTM Childhood Cancer Research Assay; Archer®FusionPlex® ALL, and Human Comprehensive Cancer Panel GeneRead Panel v2®). Overall, the panels showed a good performance in different centers and platforms, but each NGS approach presented some issues, as well as pros and cons. Moreover, a previous consensus on the analysis and reporting following international guidelines would be preferable to improve the concordance in results among centers. Our study shows the challenges posed by NGS methodology and the need to consider several aspects of the chosen NGS-targeted approach and reach a consensus before implementing it in daily practice. J Pers Med . 2020 Nov 26;10(4):244. 10.3390/jpm10040244 2075-4426 Journal of personalized medicine 33255984 http://hdl.handle.net/20.500.12105/11767 NGS-targeted panel Childhood acute lymphoblastic leukemia Next-generation sequencing Helpful Criteria When Implementing NGS Panels in Childhood Lymphoblastic Leukemia